As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of KTE-X19 for treating relapsed or refractory mantle cell lymphoma.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved.